168 related articles for article (PubMed ID: 29056443)
1. Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model.
Shin DH; Kwon GS
J Control Release; 2017 Dec; 268():176-183. PubMed ID: 29056443
[TBL] [Abstract][Full Text] [Related]
2. Epothilone B-based 3-in-1 polymeric micelle for anticancer drug therapy.
Shin DH; Kwon GS
Int J Pharm; 2017 Feb; 518(1-2):307-311. PubMed ID: 28062368
[TBL] [Abstract][Full Text] [Related]
3. Thermosensitive poly-(d,l-lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly-(d,l-lactide-co-glycolide) hydrogels for multi-drug delivery.
Cho H; Kwon GS
J Drug Target; 2014 Aug; 22(7):669-77. PubMed ID: 24964052
[TBL] [Abstract][Full Text] [Related]
4. Proof-of-Concept of Polymeric Sol-Gels in Multi-Drug Delivery and Intraoperative Image-Guided Surgery for Peritoneal Ovarian Cancer.
McKenzie M; Betts D; Suh A; Bui K; Tang R; Liang K; Achilefu S; Kwon GS; Cho H
Pharm Res; 2016 Sep; 33(9):2298-306. PubMed ID: 27283829
[TBL] [Abstract][Full Text] [Related]
5. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.
Shin HC; Alani AW; Cho H; Bae Y; Kolesar JM; Kwon GS
Mol Pharm; 2011 Aug; 8(4):1257-65. PubMed ID: 21630670
[TBL] [Abstract][Full Text] [Related]
6. PEG-b-PLA micelles and PLGA-b-PEG-b-PLGA sol-gels for drug delivery.
Cho H; Gao J; Kwon GS
J Control Release; 2016 Oct; 240():191-201. PubMed ID: 26699425
[TBL] [Abstract][Full Text] [Related]
7. Dual-drug loaded micelle for combinatorial therapy targeting HIF and mTOR signaling pathways for ovarian cancer treatment.
Doddapaneni BS; Al-Fatease AM; Rao DA; Alani AWG
J Control Release; 2019 Aug; 307():272-281. PubMed ID: 31260753
[TBL] [Abstract][Full Text] [Related]
8. Oligo(Lactic Acid)
Tam YT; Repp L; Ma ZX; Feltenberger JB; Kwon GS
Pharm Res; 2019 Mar; 36(5):70. PubMed ID: 30888509
[TBL] [Abstract][Full Text] [Related]
9. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
Banerji U; Sain N; Sharp SY; Valenti M; Asad Y; Ruddle R; Raynaud F; Walton M; Eccles SA; Judson I; Jackman AL; Workman P
Cancer Chemother Pharmacol; 2008 Oct; 62(5):769-78. PubMed ID: 18193424
[TBL] [Abstract][Full Text] [Related]
10. Preparation of Folic Acid-Targeted Temperature-Sensitive Magnetoliposomes and their Antitumor Effects In Vitro and In Vivo.
Wang X; Yang R; Yuan C; An Y; Tang Q; Chen D
Target Oncol; 2018 Aug; 13(4):481-494. PubMed ID: 29992403
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin.
Shin HC; Cho H; Lai TC; Kozak KR; Kolesar JM; Kwon GS
J Control Release; 2012 Oct; 163(1):93-9. PubMed ID: 22549011
[TBL] [Abstract][Full Text] [Related]
12. Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin.
Pradhan R; Ramasamy T; Choi JY; Kim JH; Poudel BK; Tak JW; Nukolova N; Choi HG; Yong CS; Kim JO
Carbohydr Polym; 2015 Jun; 123():313-23. PubMed ID: 25843864
[TBL] [Abstract][Full Text] [Related]
13. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.
Cho H; Lai TC; Kwon GS
J Control Release; 2013 Feb; 166(1):1-9. PubMed ID: 23246471
[TBL] [Abstract][Full Text] [Related]
14. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
Roforth MM; Tan C
Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment-labile polymer-doxorubicin conjugate thermogel combined with docetaxel for in situ synergistic chemotherapy of hepatoma.
Zhang Y; Zhang J; Xu W; Xiao G; Ding J; Chen X
Acta Biomater; 2018 Sep; 77():63-73. PubMed ID: 30006312
[TBL] [Abstract][Full Text] [Related]
16. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
[TBL] [Abstract][Full Text] [Related]
17. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
18. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer.
Saxena V; Naguib Y; Hussain MD
Colloids Surf B Biointerfaces; 2012 Jun; 94():274-80. PubMed ID: 22377218
[TBL] [Abstract][Full Text] [Related]
19. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
